Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 3/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22620711 | 0.87 | KDM4E (0.56) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL913891 | 0.87 | KDM4E (0.56) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2204502 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5622391 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4044123 | 0.85 | CDK1 (0.57) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL15904734 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6303402 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2134591 | 0.84 | FLT3 (0.58) | KDM4EALDH1A1MAPTHPGDLMNA | |
| SCHEMBL22620710 | 0.84 | KDM4E (0.53) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL7884853 | 0.84 | KDM4E (0.53) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105816453-B | Substituted tricyclic acid derivatives as S1P1 receptor agonists for the treatment of autoimmune and inflammatory disorders | 艾尼纳制药公司 | 2021-03-05 | — | — | CN | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2367817-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Via Pharmaceuticals, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| EP-1042287-A1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| EP-1042288-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2000-10-11 | — | — | EP | disclosed |
| US-5977100-A | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| WO-1999033801-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999033800-A1 | INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
| US-5834454-A | TREATMENT OF ANGINA, ISCHEMIA, ARRHYTHMIA | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0787728-A1 | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-08-06 | — | — | EP | disclosed |
| US-5428043-A | Tricyclic-cyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0441517-A2 | Tricyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1991-08-14 | — | — | EP | disclosed |
| US-4053624-A | HYPOGLYCEMIC AGENTS | BOEHRINGER MANNHEIM GMBH (DT) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | KDM4E 2709/4885ALDH1A1 586/4885RAB9A 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.